Articles related to NEURODEGENERATIVE DISEASES

Survey responses from 5,797 Fox Insight participants suggest sleep disturbances, autonomic dysfunction, and emotional changes preceded Parkinson’s disease diagnosis by more than a decade in a substantial proportion of respondents.

The LRRK2 inhibitor BIIB122 failed to slow disease progression versus placebo in 648 early-stage idiopathic Parkinson’s patients in the Phase 2b LUMA trial, leading Biogen and Denali to discontinue joint development.

Researchers are increasingly studying peripheral biomarkers in high-risk populations to improve diagnosis and prediction, with standard therapies currently limited to temporary symptom relief.

Caregiver burden is common, cumulative, and often unspoken, manifesting as fatigue, depression, irritability, and social withdrawal.

According to Karthikeyan Tangavelou, PhD, a professor in the Department of Molecular Genetics & Microbiology at the UNM School of Medicine: “If you stop tau synthesis by targeting OTULIN in neurons, you can restore a healthy brain and prevent brain aging.”

By desynchronizing pathological rhythms, neuromodulation acts to induce plastic changes in thalamocortical circuits.